Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of
acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment,
and 4 weeks safety follow-up. All patients meeting the eligibility criteria will be
randomized to one of the three treatment groups--one of two doses of RGH-188 or placebo